Profile Response Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

Molecular Profile BRAF V600E
Therapy Tovorafenib
Indication/Tumor Type low grade glioma
Response Type predicted - sensitive


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
BRAF V600E low grade glioma predicted - sensitive Tovorafenib Phase II Actionable In a Phase II trial (FIREFLY-1), Tovorafenib (MLN2480) treatment was well-tolerated and resulted in an overall response rate of 64% (44/69, 3 complete responses, 41 partial responses (10 unconfirmed)) and a clinical benefit rate of 91% in pediatric patients with low-grade glioma harboring BRAF fusions (n=64) or BRAF V600E (n=13) (J Clin Oncol 41, 2023 (suppl 16; abstr 10004); NCT04775485). detail...
PubMed Id Reference Title Details
Clinical activity of pan-RAF inhibitor tovorafenib in the registrational pediatric low-grade glioma arm of the phase 2 FIREFLY-1 (PNOC026) study Full reference...